DSM421, identified by its CAS number 2011769-21-2, is a chemical compound that has garnered attention in the field of medicinal chemistry, particularly for its potential therapeutic applications. While specific details about its structure and properties may vary, compounds like DSM421 are typically characterized by their molecular weight, solubility, and stability under various conditions. Such substances often exhibit specific biological activities, which may include interactions with particular receptors or enzymes, making them candidates for drug development. The safety profile, including toxicity and pharmacokinetics, is also crucial for evaluating its suitability for therapeutic use. Additionally, DSM421 may undergo various forms of analysis, such as spectroscopic methods, to elucidate its chemical structure and confirm its identity. As research progresses, more detailed information regarding its efficacy, mechanism of action, and potential side effects will likely emerge, contributing to a better understanding of its role in pharmacology.

DSM421 is a dihydroorotate Dehydrogenase Inhibitor (DHODH) with Improved Drug-like Properties for Treatment and Prevention of Malaria. SM421 showed equal activity against both P. falciparum and P. vivax field isolates. DSM421 has the potential to be developed as a single-dose cure or once-weekly  chemopreventative for both P. falciparum and P. vivax malaria, leading to its advancement as a preclinical development candidate.

DSM421

2011769-21-2: DSM421, identified by its CAS number 2011769-21-2, is a chemical compound that has garnered attention in the field of medicinal chemistry, particularly for its potential therapeutic applications. While specific details about its structure and properties may vary, compounds like DSM421 are typically characterized by their molecular weight, solubility, and stability under various conditions. Such substances often exhibit specific biological activities, which may include interactions with particular receptors or enzymes, making them candidates for drug development. The safety profile, including toxicity and pharmacokinetics, is also crucial for evaluating its suitability for therapeutic use. Additionally, DSM421 may undergo various forms of analysis, such as spectroscopic methods, to elucidate its chemical structure and confirm its identity. As research progresses, more detailed information regarding its efficacy, mechanism of action, and potential side effects will likely emerge, contributing to a better understanding of its role in pharmacology.

<p>DSM421 (DSM-421) is a dihydrodehydrogenase inhibitor (DHODH) that is in preclinical development as a potential treatment option for malaria and has shown</p>

CAS 2011769-21-2

DSM421

DSM421

Ref: 54-BUP15206

DSM421

Ref: TM-T27214